The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

IV.a

Bronchospasm - Wheezing - Asthma

Publications

Bernstein BJ, Troner MB

Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide.

Pharmacotherapy. 1999;19(8):989-91

Hudson MM, Weinstein HJ, Donaldson SS, Greenwald C, Kun L, Tarbell NJ, Humphrey WA, Rupp C, Marina NM, Wilimas J

Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993;11(6):1080-4

O'Dwyer PJ, Weiss RB

Hypersensitivity reactions induced by etoposide.

Cancer treatment reports. 1984;68(7-8):959-61